DISCOUNT OPTIONSSCHEIN - MODERNA | Market Closed - Deutsche Boerse AG 18:53:34 14/06/2024 BST | ||
| 1.03 EUR | +87.27% |
|
| Current month | +5.10% | ||
| 1 month | -39.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 1.03 | +87.27% |
| 13/06/24 | 0.55 | +34.15% |
| 12/06/24 | 0.41 | -19.61% |
| 11/06/24 | 0.51 | -5.56% |
| 10/06/24 | 0.54 | +25.58% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 06:53 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU1SU1 |
| ISIN | DE000VU1SU10 |
| Date issued | 05/01/2023 |
| Strike | 150 $ |
| Maturity | 21/06/2024 (5 Days) |
| Parity | 10 : 1 |
| Emission price | 0.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.23 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.02 € |
| Spread % | 2.06% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- Certificat